Eligix Report issue

For profit
Founded: Medford MA United States (1997)
Status: Acquired by Miltenyi Biotec, Inc. (2003)

Organization Overview

First Clinical Trial
2001
NCT00038818
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2001

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Other Trials (1)

cd8 depleted donor lymphocyte (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1